News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Immunic, Inc. highlights its 2024 accomplishments and upcoming milestones, including positive trial results for vidofludimus calcium in multiple sclerosis. Strengthened team and secured private placement for future growth -
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. to Participate in Investor Conference in December
Immunic, Inc. to Participate in Investor Conference in December. Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing therapies for chronic inflammatory and autoimmune diseases, announces participation in Piper Sandler 36th Annual Healthcare Conference in New York -